Meloxicam/Kleva 15 Mg / 1,5 Ml (Meloxicam)

Meloxicam works by preferentially inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the synthesis of prostaglandins that mediate inflammation, pain, and fever, thereby providing analgesic and anti‑inflammatory effects.

The specific dose and frequency of meloxicam are determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual risk factors. The prescriber will set the appropriate regimen.

The safety of meloxicam in pregnancy and lactation has not been established. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Meloxicam offers a higher selectivity for COX‑2 compared with many non‑selective NSAIDs, which may result in a lower incidence of gastrointestinal irritation while still providing effective analgesia. However, individual response and safety profiles vary, so clinicians choose based on patient-specific factors.

Meloxicam/Kleva 15 mg/1.5 mL should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintaining the cold chain preserves product stability.

The product is supplied as an injectable solution for intramuscular administration. A healthcare professional injects the prescribed volume into the appropriate muscle site using aseptic technique.

Serious risks include gastrointestinal ulceration or bleeding, severe skin reactions such as Stevens‑Johnson syndrome, renal impairment, hepatic dysfunction, and increased cardiovascular events. Patients should be monitored for signs of these conditions.

Meloxicam is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe hepatic or renal impairment, and patients in the third trimester of pregnancy.